The dermatology CRO market would grow at a CAGR of 6.88% over the predicted time frame. The market is expected to increase in value from US$ 5.11 Bn in 2022 to US$ 8.7 Bn in 2030.
The on dermatology CRO Market, which provides a business strategy, research & development activities, concise outline of the market valuation, valuable insights pertaining to market share, size, supply chain analysis, competitive landscape and regional proliferation of this industry.
Download Free Sample@ https://www.precedenceresearch.com/sample/2403
A recent report provides crucial insights along with application based and forecast information in the Global Dermatology CRO Market. The report provides a comprehensive analysis of key factors that are expected to drive the growth of this market. This study also provides a detailed overview of the opportunities along with the current trends observed in the Dermatology CRO market.
A quantitative analysis of the industry is compiled for a period of 10 years in order to assist players to grow in the market. Insights on specific revenue figures generated are also given in the report, along with projected revenue at the end of the forecast period.
Companies and Manufacturers Covered
The study covers key players operating in the market along with prime schemes and strategies implemented by each player to hold high positions in the industry. Such a tough vendor landscape provides a competitive outlook of the industry, consequently existing as a key insight. These insights were thoroughly analysed and prime business strategies and products that offer high revenue generation capacities were identified. Key players of the global Dermatology CRO market are included as given below:
Dermatology CRO Market Key Players
- IQVIA HOLDINGS INC.
- Covance Inc.
- Pharmaceutical Product Development, LLC (PPD)
- Parexel International Corporation
- Charles River Laboratories International, Inc.
- Icon, Plc
- Medidata Solutions, Inc.
- Syneos Health
- Pharmaron
- GVK Biosciences Private Limited
- Wuxi AppTec
- MEDPACE HOLDINGS, INC.
- PRA Health Sciences
- CTI Clinical Trial & Consulting
- Bioskin
- Proinnovera
- Biorasi
- Javara
- TFS
Market Segments
By Service
- Project Management/Clinical Supply Management
- Data Management
- Regulatory/Medical Affairs
- Medical Writing
- Clinical Monitoring
- Quality Management/Assurance
- Bio-statistics
- Investigator Payments
- Laboratory
- Patient and Site Recruitment
- Technology
- Others
By Type
- Drug Discovery
- Target Validation
- Lead Identification
- Lead optimization
- Preclinical
- Clinical
By Phase Type
- Phase I
- Phase II
- Phase III
- Phase IV
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East & Africa (MEA)
Report Objectives
- To define, describe, and forecast the global dermatology CRO market based on product, and region
- To provide detailed information regarding the major factors influencing the growth of the market (drivers, opportunities, and industry-specific challenges)
- To strategically analyze micromarkets1 with respect to individual growth trends, future prospects, and contributions to the total market
- To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of market segments with respect to four main regions—North America, Europe, Asia Pacific and the Rest of the World (RoW)2
- To strategically profile key players and comprehensively analyze their product portfolios, market shares, and core competencies3
- To track and analyze competitive developments such as acquisitions, expansions, new product launches, and partnerships in the dermatology CRO market
Table of Content
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Dermatology CRO Market
5.1. COVID-19 Landscape: Dermatology CRO Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Dermatology CRO Market, By Service
8.1. Dermatology CRO Market, by Service, 2022-2030
8.1.1 Project Management/Clinical Supply Management
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Data Management
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Regulatory/Medical Affairs
8.1.3.1. Market Revenue and Forecast (2017-2030)
8.1.4. Regulatory/Medical Affairs
8.1.4.1. Market Revenue and Forecast (2017-2030)
8.1.5. Clinical Monitoring
8.1.5.1. Market Revenue and Forecast (2017-2030)
8.1.6. Quality Management/Assurance
8.1.6.1. Market Revenue and Forecast (2017-2030)
8.1.7. Bio-statistics
8.1.7.1. Market Revenue and Forecast (2017-2030)
8.1.8. Investigator Payments
8.1.8.1. Market Revenue and Forecast (2017-2030)
8.1.9. Laboratory
8.1.9.1. Market Revenue and Forecast (2017-2030)
8.1.10. Clinical Monitoring
8.1.10.1. Market Revenue and Forecast (2017-2030)
8.1.11. Technology
8.1.11.1. Market Revenue and Forecast (2017-2030)
8.1.12. Clinical Monitoring
8.1.12.1. Market Revenue and Forecast (2017-2030)
8.1.13. Others
8.1.13.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Dermatology CRO Market, By Type
9.1. Dermatology CRO Market, by Type, 2022-2030
9.1.1. Drug Discovery
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Preclinical
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Clinical
9.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Dermatology CRO Market, By Phase Type
10.1. Dermatology CRO Market, by Phase Type, 2022-2030
10.1.1. Phase I
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Phase II
10.1.2.1. Market Revenue and Forecast (2017-2030)
10.1.3. Phase III
10.1.3.1. Market Revenue and Forecast (2017-2030)
10.1.4. Phase IV
10.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global Dermatology CRO Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Service (2017-2030)
11.1.2. Market Revenue and Forecast, by Type (2017-2030)
11.1.3. Market Revenue and Forecast, by Phase Type (2017-2030)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Service (2017-2030)
11.1.4.2. Market Revenue and Forecast, by Type (2017-2030)
11.1.4.3. Market Revenue and Forecast, by Phase Type (2017-2030)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Service (2017-2030)
11.1.5.2. Market Revenue and Forecast, by Type (2017-2030)
11.1.5.3. Market Revenue and Forecast, by Phase Type (2017-2030)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Service (2017-2030)
11.2.2. Market Revenue and Forecast, by Type (2017-2030)
11.2.3. Market Revenue and Forecast, by Phase Type (2017-2030)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Service (2017-2030)
11.2.4.2. Market Revenue and Forecast, by Type (2017-2030)
11.2.4.3. Market Revenue and Forecast, by Phase Type (2017-2030)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Service (2017-2030)
11.2.5.2. Market Revenue and Forecast, by Type (2017-2030)
11.2.5.3. Market Revenue and Forecast, by Phase Type (2017-2030)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Service (2017-2030)
11.2.6.2. Market Revenue and Forecast, by Type (2017-2030)
11.2.6.3. Market Revenue and Forecast, by Phase Type (2017-2030)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Service (2017-2030)
11.2.7.2. Market Revenue and Forecast, by Type (2017-2030)
11.2.7.3. Market Revenue and Forecast, by Phase Type (2017-2030)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Service (2017-2030)
11.3.2. Market Revenue and Forecast, by Type (2017-2030)
11.3.3. Market Revenue and Forecast, by Phase Type (2017-2030)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Service (2017-2030)
11.3.4.2. Market Revenue and Forecast, by Type (2017-2030)
11.3.4.3. Market Revenue and Forecast, by Phase Type (2017-2030)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Service (2017-2030)
11.3.5.2. Market Revenue and Forecast, by Type (2017-2030)
11.3.5.3. Market Revenue and Forecast, by Phase Type (2017-2030)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Service (2017-2030)
11.3.6.2. Market Revenue and Forecast, by Type (2017-2030)
11.3.6.3. Market Revenue and Forecast, by Phase Type (2017-2030)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Service (2017-2030)
11.3.7.2. Market Revenue and Forecast, by Type (2017-2030)
11.3.7.3. Market Revenue and Forecast, by Phase Type (2017-2030)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Service (2017-2030)
11.4.2. Market Revenue and Forecast, by Type (2017-2030)
11.4.3. Market Revenue and Forecast, by Phase Type (2017-2030)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Service (2017-2030)
11.4.4.2. Market Revenue and Forecast, by Type (2017-2030)
11.4.4.3. Market Revenue and Forecast, by Phase Type (2017-2030)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Service (2017-2030)
11.4.5.2. Market Revenue and Forecast, by Type (2017-2030)
11.4.5.3. Market Revenue and Forecast, by Phase Type (2017-2030)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Service (2017-2030)
11.4.6.2. Market Revenue and Forecast, by Type (2017-2030)
11.4.6.3. Market Revenue and Forecast, by Phase Type (2017-2030)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Service (2017-2030)
11.4.7.2. Market Revenue and Forecast, by Type (2017-2030)
11.4.7.3. Market Revenue and Forecast, by Phase Type (2017-2030)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Service (2017-2030)
11.5.2. Market Revenue and Forecast, by Type (2017-2030)
11.5.3. Market Revenue and Forecast, by Phase Type (2017-2030)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Service (2017-2030)
11.5.4.2. Market Revenue and Forecast, by Type (2017-2030)
11.5.4.3. Market Revenue and Forecast, by Phase Type (2017-2030)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Service (2017-2030)
11.5.5.2. Market Revenue and Forecast, by Type (2017-2030)
11.5.5.3. Market Revenue and Forecast, by Phase Type (2017-2030)
Chapter 12. Company Profiles
12.1. IQVIA HOLDINGS INC.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Covance Inc.
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Pharmaceutical Product Development, LLC (PPD)
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Parexel International Corporation
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Charles River Laboratories International, Inc.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Icon, Plc
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Medidata Solutions, Inc.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Syneos Health
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Pharmaron
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. GVK Biosciences Private Limited
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Contact Us:
Precedence Research
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1 774 402 6168
Email: sales@precedenceresearch.com
Website: https://www.precedenceresearch.com
0 Comments